EP1148877A4 - Methods for inhibiting bone resorption - Google Patents

Methods for inhibiting bone resorption

Info

Publication number
EP1148877A4
EP1148877A4 EP99970321A EP99970321A EP1148877A4 EP 1148877 A4 EP1148877 A4 EP 1148877A4 EP 99970321 A EP99970321 A EP 99970321A EP 99970321 A EP99970321 A EP 99970321A EP 1148877 A4 EP1148877 A4 EP 1148877A4
Authority
EP
European Patent Office
Prior art keywords
methods
bone resorption
inhibiting bone
inhibiting
resorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99970321A
Other languages
German (de)
French (fr)
Other versions
EP1148877A1 (en
Inventor
Shun-Ichi Harada
Mohamed Machwate
Gideon A Rodan
Marc Labelle
Kathleen Metters
Robert N Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Merck and Co Inc
Original Assignee
Merck Frosst Canada and Co
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9824572.3A external-priority patent/GB9824572D0/en
Application filed by Merck Frosst Canada and Co, Merck and Co Inc filed Critical Merck Frosst Canada and Co
Publication of EP1148877A1 publication Critical patent/EP1148877A1/en
Publication of EP1148877A4 publication Critical patent/EP1148877A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
EP99970321A 1998-10-15 1999-10-12 Methods for inhibiting bone resorption Withdrawn EP1148877A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10433998P 1998-10-15 1998-10-15
US104339P 1998-10-15
GB9824572 1998-11-09
GBGB9824572.3A GB9824572D0 (en) 1998-11-09 1998-11-09 Methods for inhibiting bone resorption
PCT/US1999/023616 WO2000021532A1 (en) 1998-10-15 1999-10-12 Methods for inhibiting bone resorption

Publications (2)

Publication Number Publication Date
EP1148877A1 EP1148877A1 (en) 2001-10-31
EP1148877A4 true EP1148877A4 (en) 2003-01-22

Family

ID=26314644

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99970321A Withdrawn EP1148877A4 (en) 1998-10-15 1999-10-12 Methods for inhibiting bone resorption

Country Status (5)

Country Link
EP (1) EP1148877A4 (en)
JP (1) JP2002527393A (en)
AU (1) AU1444200A (en)
CA (1) CA2346038A1 (en)
WO (1) WO2000021532A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
CN1413190A (en) * 1999-12-22 2003-04-23 辉瑞产品公司 EP4 receptor selective agonists in treatment of osteoporosis
HN2001000224A (en) 2000-10-19 2002-06-13 Pfizer IMIDAZOL COMPOUNDS CONDENSED WITH ARILO OR HETEROARILO AS ANTI - INFLAMMATORY AND ANALGESIC AGENTS.
SK5562003A3 (en) 2000-11-27 2004-08-03 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
AU2002328338C1 (en) 2001-07-16 2009-01-08 Ono Pharmaceutical Co., Ltd 2 pyrrolidone derivatives as prostanoid agonists
PL368046A1 (en) 2001-07-16 2005-03-21 F.Hoffmann-La Roche Ag Prostaglandin analogues_as ep4 receptor agonists
KR20070087078A (en) 2001-07-23 2007-08-27 오노 야꾸힝 고교 가부시키가이샤 Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
WO2003030911A1 (en) * 2001-10-08 2003-04-17 Medical Research Council Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus
JP2006515015A (en) 2003-01-10 2006-05-18 エフ.ホフマン−ラ ロシュ アーゲー 2-Piperidone derivatives as prostaglandin agonists
US7179820B2 (en) 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
UY30121A1 (en) 2006-02-03 2007-08-31 Glaxo Group Ltd NEW COMPOUNDS
US20080167377A1 (en) 2006-12-15 2008-07-10 Alessandra Gaiba Novel compounds
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
JPWO2010087425A1 (en) 2009-01-30 2012-08-02 国立大学法人京都大学 Prostate cancer progression inhibitor and progression inhibition method
JP2015522528A (en) 2012-05-09 2015-08-06 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Method and pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526001A1 (en) * 1991-07-03 1993-02-03 Merck & Co. Inc. Substituted triazolinones

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411980A (en) * 1989-07-28 1995-05-02 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526001A1 (en) * 1991-07-03 1993-02-03 Merck & Co. Inc. Substituted triazolinones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0021532A1 *

Also Published As

Publication number Publication date
CA2346038A1 (en) 2000-04-20
AU1444200A (en) 2000-05-01
EP1148877A1 (en) 2001-10-31
WO2000021532A1 (en) 2000-04-20
JP2002527393A (en) 2002-08-27

Similar Documents

Publication Publication Date Title
EP1088333A4 (en) Compositions and methods for inhibiting bone resorption
HUP0104836A3 (en) Bone fixation system
HK1021499A1 (en) A surgical system for dermablation
HU9904702D0 (en) Method for providing refrigeration
IL118196A0 (en) Methods for inhibiting bone loss
AU3359697A (en) Bone resorption inhibitors
GB9812103D0 (en) Surgical implant
EP1148877A4 (en) Methods for inhibiting bone resorption
GB9819243D0 (en) Method for inhibiting bone resorption
EP1089750A4 (en) Compositions and methods for inhibiting bone resorption
GB9824572D0 (en) Methods for inhibiting bone resorption
EP1142579A4 (en) Bone resorption inhibitors
AU137972S (en) Implant
GB9810885D0 (en) Methods of inhibiting bone resorption
GB9809791D0 (en) Methods of inhibiting bone resorption
GB9822699D0 (en) Methods of inhibiting bone resorption
GB9819126D0 (en) Compositions and methods for inhibiting bone resorption
GB9817170D0 (en) Compositions and methods for inhibiting bone resorption
GB9822330D0 (en) Compositions and methods for inhibiting bone resorption
AU741818C (en) Method for inhibiting bone resorption
GB9826207D0 (en) Bone conditions
GB9821388D0 (en) Spinal implants
GB9824574D0 (en) Methods for regulating bone formation
HU9801479D0 (en) Mechanical tachitoscope for improving fixation width
ZA986040B (en) Orthopedic supports

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010515

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010515;LT PAYMENT 20010515;LV PAYMENT 20010515;MK PAYMENT 20010515;RO PAYMENT 20010515;SI PAYMENT 20010515

A4 Supplementary search report drawn up and despatched

Effective date: 20021205

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030522

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040309